NL-OMON24861尚未招募不适用
Dose-to-target of etanercept treatment: A dose-tapering randomized controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
Jan van Breemen Research Institute | Reade0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 250
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosis: RA (according to the American College of Rheumatology 1987 criteria), or PsA (according to the Classification of Psoriatic Arthritis criteria) or AS (according to the 1984 New York Criteria);
- •2. Treatment with etanercept 50 mg SC weekly (or 25 mg SC twice weekly) for at least 6 subsequent months;
排除标准
- •Planned reasons for treatment discontinuation.
研究者
相似试验
尚未招募
不适用
Dose-to-target of etanercept treatment in patients with juvenile idiopathic arthritis in patients age 12 years and older.etanercept, juvenile idiopathic arthritis, dose tapering, discontinuationNL-OMON20690Jan van Breemen Instituut, Reade40
招募中
不适用
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.rheumatoid arthritisankylosing spondylitispsoriatic arthritis10003816NL-OMON38584Jan van Breemen Instituut250
招募中
不适用
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with juvenile idiopathic arthritis in patients age 12 years and older.10003816juvenile idiopathic arthritisNL-OMON40793Jan van Breemen Instituut40
已完成
不适用
Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT02030613Assistance Publique - Hôpitaux de Paris126
进行中（未招募）
1 期
Targeted treatment early with etanercept and methotrexate or methotrexate with treat to target (standard) care for treatment-naive early rheumatoid arthritis patients, based on baseline naive T-cell frequency.Rheumatoid ArthritisEUCTR2016-002344-16-GBniversity of Leeds106